IBSA Institut Biochimique SA

IBSA Group

IBSA (Institut Biochimique SA) is a Swiss multinational pharmaceutical Company, founded in 1945 in Lugano. Today, its products are present in over 90 Countries on 5 continents, through the Company’s 17 subsidiaries located in Europe, China, and the United States. The company has a consolidated turnover of 800 million CHF, and employs over 2,000 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents, plus others under development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, consumer health. It is also one of the largest operators worldwide in the area of reproductive medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on four pillars: Person, Innovation, Quality and Responsibility.

Aesthetic medicine aims to improve and maintain the aesthetic wellness of the skin through a thorough analysis of the patient’s systemic and local conditions, the formulation of a detailed diagnosis and the creation of therapeutic strategies.

In this area, IBSA provides a complete range of products based on the Hydrolift® action concept. Hydrolift® Action is a novel approach that aims to counter the physiological decrease in the hyaluronic acid (HA) present in the skin, to restore moisture, elasticity and firmness.

This approach is the expression of the synergistic action resulting from the use of selected hyaluronic acids produced using patented technology that, when administered in combination, create the optimal conditions for preventing and countering the aging process.

In recent years, the portfolio has been enhanced by the introduction of an innovative product containing a solution of thermally-stabilised, hybrid cooperative ultrapure hyaluronic acid complexes, using IBSA’s patented hybrid NAHYCO® technology.

Pain and Inflammation

Pain relief has a long history that dates back more than 5000 years. However, it was only in recent years that we acquired adequate levels of knowledge concerning pathophysiology, nociception and the mechanism of action of analgesic substances.

Irrespective of its origin, pain, especially when chronic, is a potentially invalidating condition that can compromise the quality of life of individuals, preventing them from getting around, working and leading an active life.

In the whole of Europe, approximately 500 million work days are lost each year due to chronic and acute pain, with an enormous social and economic impact.

Of the various remedies available for symptomatic pain treatment, nonsteroidal anti-inflammatory drugs (NSAIDs) have been commonly used for some time, and are indicated in a vast variety of conditions, such as muscle, tendon and joint injuries, backache, menstrual pain, toothache and headache.

IBSA has placed on the global market innovative formulations, such as drug-in-adhesive medicated patches using hydrogel technology, that afford optimum absorption and rapid relief of pain caused by soft tissue injuries, musculoskeletal disorders and other clinical conditions characterised by acute and chronic pain.